0.75
+0.0356(+5.00%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.98 |
| Day High | 1.04 |
| Day Low | 0.73 |
| 52-Week High | 6.89 |
| 52-Week Low | 0.64 |
| Volume | 72.83M |
| Average Volume | 1.34M |
| Market Cap | 12.13M |
| PE | -18.7 |
| EPS | -0.04 |
| Moving Average 50 Days | 0.89 |
| Moving Average 200 Days | 2.49 |
| Change | 0.04 |
If you invested $1000 in iBio, Inc. (IBIO) 10 years ago, it would be worth $0.17 as of June 24, 2025 at a share price of $0.87. Whereas If you bought $1000 worth of iBio, Inc. (IBIO) shares 5 years ago, it would be worth $1.12 as of June 24, 2025 at a share price of $0.87.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
GlobeNewswire Inc.
Yesterday at 11:00 AM GMT
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
GlobeNewswire Inc.
Jun 23, 2025 8:15 PM GMT
Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body co